PRRSV VLP 

Porcine reproductive and respiratory syndrome virus (PRRSV) virus-like particles (VLPs) are self-assembled, non-infectious structures that mimic the PRRSV virion. These particles lack viral RNA, making them safe for use in vaccine development, diagnostics, and immunological research. PRRSV is a significant pathogen in swine, causing reproductive failure in sows and respiratory issues in pigs, leading to substantial economic losses worldwide.

Structure of PRRSV VLPs

PRRSV VLPs are primarily composed of the structural proteins of the virus:

  • Glycoproteins (GP2, GP3, GP4, GP5): Embedded in the lipid envelope; GP5 is the major envelope glycoprotein and a key target for neutralizing antibodies.
  • Matrix protein (M): Provides structural support and interacts with the envelope and capsid.
  • Nucleocapsid protein (N): Forms the internal core of the virus but is absent in most VLPs as they lack the genome.
Production Systems

PRRSV VLPs are typically expressed in:

  • Insect Cells: Using the baculovirus expression system, which ensures proper folding of glycoproteins.
  • Mammalian Cells: Provides authentic post-translational modifications, including glycosylation, for enhanced antigenicity.
  • Yeast Systems: An emerging option for cost-effective production, though glycosylation patterns may differ.
Applications
  • Vaccines
    • Prophylactic Vaccines: PRRSV VLPs elicit strong immune responses, especially neutralizing antibodies against GP5, offering potential protection against PRRSV infection.
    • Next-Generation Vaccines: VLP-based platforms are being developed to improve cross-protection against diverse PRRSV strains.
  • Immunological Research
    • PRRSV VLPs are used to study the virus-host interactions, especially mechanisms of immune evasion and neutralization.
  • Diagnostics
    • Serve as antigens in diagnostic assays to detect PRRSV-specific antibodies, aiding in disease surveillance and control.
  • Therapeutic Development
    • Explored as carriers for delivering antiviral agents or immunomodulatory molecules targeting PRRSV.

PRRSV virus-like particles represent a promising approach to controlling PRRSV infections through safe and effective vaccines. They also hold potential for use in diagnostics and therapeutic delivery. Ongoing advancements in VLP technology and production systems aim to enhance their efficacy and applicability in combating PRRSV in the global swine industry.

For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD